Literature DB >> 16432754

Mycobacterium hsp65 DNA entrapped into TDM-loaded PLGA microspheres induces protection in mice against Leishmania (Leishmania) major infection.

Eduardo Antonio Ferraz Coelho1, Carlos Alberto Pereira Tavares, Karla de Melo Lima, Célio Lopes Silva, José Maciel Rodrigues, Ana Paula Fernandes.   

Abstract

Heat shock proteins (HSPs) are highly conserved among different organisms. A mycobacterial HSP65 DNA vaccine was previously shown to have prophylactic and immunotherapeutic effects against Mycobacterium tuberculosis infection in mice. Here, BALB/c mice were immunized with mycobacterial DNA-hsp65 or with DNA-hsp65 and trehalose dymicolate (TDM), both carried by biodegradable microspheres (MHSP/TDM), and challenged with Leishmania (Leishmania) major. MHSP/TDM conferred protection against L. major infection, as indicated by a significant reduction of edema and parasite loads in infected tissues. Although high levels of interferon-gamma and low levels of interleukin (IL)-4 and IL-10 were detected in mice immunized with DNA-hsp65 or MHSP/TDM, only animals immunized with MHSP/TDM displayed a consistent Th1 immune response, i.e., significantly higher levels of anti-soluble Leishmania antigen (SLA) immunoglobulin G (IgG)2a and low anti-SLA IgG1 antibodies. These findings indicate that encapsulated MHSP/TDM is more immunogenic than naked hsp65 DNA, and has great potential to improve vaccine effectiveness against leishmaniasis and tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16432754     DOI: 10.1007/s00436-005-0088-5

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  49 in total

1.  Efficacy of DNA-hsp65 vaccination for tuberculosis varies with method of DNA introduction in vivo.

Authors:  K M Lima; S A dos Santos; R R Santos; I T Brandão; J M Rodrigues; C L Silva
Journal:  Vaccine       Date:  2003-12-08       Impact factor: 3.641

Review 2.  A role for heat shock proteins in antigen processing and presentation.

Authors:  S K Pierce; D C DeNagel; A M VanBuskirk
Journal:  Curr Top Microbiol Immunol       Date:  1991       Impact factor: 4.291

3.  IL-4 rapidly produced by V beta 4 V alpha 8 CD4+ T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice.

Authors:  P Launois; I Maillard; S Pingel; K G Swihart; I Xénarios; H Acha-Orbea; H Diggelmann; R M Locksley; H R MacDonald; J A Louis
Journal:  Immunity       Date:  1997-05       Impact factor: 31.745

4.  Protection against Leishmania donovani infection by DNA vaccination: increased DNA vaccination efficiency through inhibiting the cellular p53 response.

Authors:  A Ghosh; S Labrecque; G Matlashewski
Journal:  Vaccine       Date:  2001-04-30       Impact factor: 3.641

5.  Immunostimulatory properties of the Leishmania infantum heat shock proteins HSP70 and HSP83.

Authors:  A I Rico; S O Angel; C Alonso; J M Requena
Journal:  Mol Immunol       Date:  1999-12       Impact factor: 4.407

6.  Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and Bacillus Calmette Guérin priming.

Authors:  C Barrios; A R Lussow; J Van Embden; R Van der Zee; R Rappuoli; P Costantino; J A Louis; P H Lambert; G Del Giudice
Journal:  Eur J Immunol       Date:  1992-06       Impact factor: 5.532

7.  Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection.

Authors:  Eduardo Antonio Ferraz Coelho; Carlos Alberto Pereira Tavares; Fernando Aécio Amorim Carvalho; Karina Figueiredo Chaves; Kadima Nayara Teixeira; Rafaela Chitarra Rodrigues; Hugues Charest; Greg Matlashewski; Ricardo Tostes Gazzinelli; Ana Paula Fernandes
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

8.  A comparative evaluation of different DNA vaccine candidates against experimental murine leishmaniasis due to L. major.

Authors:  Sami Ben Hadj Ahmed; Chokri Bahloul; Cyrine Robbana; Souhir Askri; Koussay Dellagi
Journal:  Vaccine       Date:  2004-04-16       Impact factor: 3.641

9.  Immune responses associated with susceptibility of C57BL/10 mice to Leishmania amazonensis.

Authors:  L C Afonso; P Scott
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

Review 10.  Vaccines for parasitic and bacterial diseases.

Authors:  Steven G Reed; Antonio Campos-Neto
Journal:  Curr Opin Immunol       Date:  2003-08       Impact factor: 7.486

View more
  12 in total

1.  High loading efficiency and tunable release of plasmid DNA encapsulated in submicron particles fabricated from PLGA conjugated with poly-L-lysine.

Authors:  Jeremy S Blum; W Mark Saltzman
Journal:  J Control Release       Date:  2008-04-16       Impact factor: 9.776

2.  Therapeutic DNA vaccine reduces schistosoma mansoni-induced tissue damage through cytokine balance and decreased migration of myofibroblasts.

Authors:  Fabiani Gai Frantz; Toshihiro Ito; Karen Angélica Cavassani; Cory M Hogaboam; Célio Lopes Silva; Steven L Kunkel; Lúcia H Faccioli
Journal:  Am J Pathol       Date:  2011-05-18       Impact factor: 4.307

3.  Immunization against leishmaniasis by PLGA nanospheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN.

Authors:  Mohsen Tafaghodi; Ali Khamesipour; Mahmoud R Jaafari
Journal:  Parasitol Res       Date:  2010-12-02       Impact factor: 2.289

4.  A Leishmania-specific hypothetical protein expressed in both promastigote and amastigote stages of Leishmania infantum employed for the serodiagnosis of, and as a vaccine candidate against, visceral leishmaniasis.

Authors:  Vivian T Martins; Mariana C Duarte; Miguel A Chávez-Fumagalli; Daniel Menezes-Souza; Cecília S P Coelho; Danielle F de Magalhães-Soares; Ana Paula Fernandes; Manuel Soto; Carlos A P Tavares; Eduardo A F Coelho
Journal:  Parasit Vectors       Date:  2015-07-11       Impact factor: 3.876

5.  Helminth coinfection does not affect therapeutic effect of a DNA vaccine in mice harboring tuberculosis.

Authors:  Fabiani G Frantz; Rogério S Rosada; Camila Peres-Buzalaf; Franciele R T Perusso; Vanderlei Rodrigues; Simone G Ramos; Steven L Kunkel; Célio L Silva; Lúcia H Faccioli
Journal:  PLoS Negl Trop Dis       Date:  2010-06-08

6.  DNA-hsp65 vaccine as therapeutic strategy to treat experimental chromoblastomycosis caused by Fonsecaea pedrosoi.

Authors:  Isaque Medeiros Siqueira; Alice Melo Ribeiro; Yanna Karla de Medeiros Nóbrega; Karina Smidt Simon; Ana Camila Oliveira Souza; Márcio Souza Jerônimo; Florêncio Figueiredo Cavalcante Neto; Célio Lopes Silva; Maria Sueli Soares Felipe; Anamélia Lorenzetti Bocca
Journal:  Mycopathologia       Date:  2012-11-22       Impact factor: 2.574

Review 7.  Current progress in gene delivery technology based on chemical methods and nano-carriers.

Authors:  Lian Jin; Xin Zeng; Ming Liu; Yan Deng; Nongyue He
Journal:  Theranostics       Date:  2014-01-15       Impact factor: 11.556

8.  Th1 Platform Immune Responses Against Leishmania major Induced by Thiol-Specific Antioxidant-Based DNA Vaccines.

Authors:  Fatemeh Tabatabaie; Mehdi Mahdavi; Sobhan Faezi; Abdolhossein Dalimi; Zohreh Sharifi; Lame Akhlaghi; Fatemeh Ghaffarifar
Journal:  Jundishapur J Microbiol       Date:  2014-02-01       Impact factor: 0.747

9.  Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes.

Authors:  Rogério S Rosada; Lucimara Gaziola de la Torre; Fabiani G Frantz; Ana P F Trombone; Carlos R Zárate-Bladés; Denise M Fonseca; Patrícia R M Souza; Izaíra T Brandão; Ana P Masson; Edson G Soares; Simone G Ramos; Lúcia H Faccioli; Célio L Silva; Maria H A Santana; Arlete A M Coelho-Castelo
Journal:  BMC Immunol       Date:  2008-07-22       Impact factor: 3.615

10.  Combined immunization using DNA-Sm14 and DNA-Hsp65 increases CD8+ memory T cells, reduces chronic pathology and decreases egg viability during Schistosoma mansoni infection.

Authors:  Milena Sobral Espíndola; Fabiani Gai Frantz; Luana Silva Soares; Ana Paula Masson; Cristiane Tefé-Silva; Claudia Silva Bitencourt; Sérgio Costa Oliveira; Vanderlei Rodrigues; Simone Gusmão Ramos; Célio Lopes Silva; Lúcia Helena Faccioli
Journal:  BMC Infect Dis       Date:  2014-05-16       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.